We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

DefiniGEN Licenses CRISPR-Cas9 Gene Editing Technology from Broad Institute to for Metabolic Disease Drug Development

Product News   Nov 25, 2018

 
DefiniGEN Licenses CRISPR-Cas9 Gene Editing Technology from Broad Institute to for Metabolic Disease Drug Development
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Eppendorf SmartBlock™ for Cell Thawing: Reproducible and Reliable Process

Product News

Eppendorf offers now a further building block in supporting scientists with tailored solutions for the daily lab routine.

READ MORE

Porvair Reports Ovarian Cancer Project Shows Promise

Product News

Porvair Sciences reports it has agreed with its collaborative partners to make additional investment in the CEAT project.

READ MORE

InSphero Strengthens Scientific Advisory Board To Advance Drug Discovery and Safety Solutions

Product News

InSphero AG, today announced the strengthening of its Scientific Advisory Board (SAB).

READ MORE

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE